{"id":2657,"date":"2011-01-04T13:25:15","date_gmt":"2011-01-04T18:25:15","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=2657"},"modified":"2011-01-04T13:25:15","modified_gmt":"2011-01-04T18:25:15","slug":"pharma-biotech-ink-deal-on-anti-inflammatory-candidate","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=2657","title":{"rendered":"Pharma, Biotech Ink Deal on Anti-Inflammatory Candidate"},"content":{"rendered":"<figure id=\"attachment_1753\" aria-describedby=\"caption-attachment-1753\" style=\"width: 239px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/EuroNotesCoins_USMint.gif\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-1753\" title=\"EuroNotesCoins_USMint\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/EuroNotesCoins_USMint.gif\" alt=\"Euro Notes and Coins (U.S. Mint)\" width=\"239\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/EuroNotesCoins_USMint.gif 239w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/EuroNotesCoins_USMint-150x125.gif 150w\" sizes=\"auto, (max-width: 239px) 100vw, 239px\" \/><\/a><figcaption id=\"caption-attachment-1753\" class=\"wp-caption-text\">(U.S. Mint)<\/figcaption><\/figure>\n<p>XOMA Ltd., a biotechnology company in Berkeley, California, and Les Laboratoires Servier a French pharmaceutical company, <a href=\"http:\/\/investors.xoma.com\/releasedetail.cfm?ReleaseID=541243\">announced an agreement<\/a> to develop and commercialize XOMA 052, XOMA&#8217;s anti-inflammatory drug candidate. XOMA 052 is designed to inhibit the pro-inflammatory <a href=\"http:\/\/www.medterms.com\/script\/main\/art.asp?articlekey=11937\">cytokine interleukin-1 beta<\/a> believed to be a primary trigger of pathologic inflammation in multiple diseases.<\/p>\n<p>Under the agreement, XOMA will receive $35 million upfront, as well as up to $470 million in milestone payments and tiered royalties of about 15 percent. XOMA will retain development and commercialization rights for <a href=\"http:\/\/www.medicinenet.com\/behcets_syndrome\/article.htm\">Behcet&#8217;s uveitis <\/a>and other inflammatory and oncology conditions in the U.S. and Japan. Servier receives similar rights in the rest of the world.<\/p>\n<p>Servier will fund the first $50 million of XOMA 052 development expenses and half of further expenses for the Behcet&#8217;s uveitis conditon. XOMA 052 is expected to advance into a Phase 3 trial in Behcet&#8217;s uveitis in 2011. The deal also involves funding, licensing, and commercialization rights for diabetes and cardiovascular disease conditions.<\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>XOMA Ltd., a biotechnology company in Berkeley, California, and Les Laboratoires Servier a French pharmaceutical company, announced an agreement to develop and commercialize XOMA 052, XOMA&#8217;s anti-inflammatory drug candidate. XOMA 052 is designed to inhibit the pro-inflammatory cytokine interleukin-1 beta believed to be a primary trigger of pathologic inflammation in multiple diseases. Under the agreement, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,16],"tags":[31,21,45,84,64,27],"class_list":["post-2657","post","type-post","status-publish","format-standard","hentry","category-i-p","category-ventures","tag-biomedical","tag-biotech","tag-europe","tag-licensing","tag-life-sciences","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2657"}],"version-history":[{"count":2,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2657\/revisions"}],"predecessor-version":[{"id":2659,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2657\/revisions\/2659"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}